Dr Ann Rigby-Jones
Lecturer in Pharmacology
Peninsula Medical School (Plymouth University Peninsula Schools of Medicine and Dentistry)
Lecturer in Pharmacology
PhD in Medical Studies for a thesis entitled:
The Pharmacokinetics and Pharmacodynamics of Propofol in the Critically Ill Child
Peninsula Medical School, Universities of Exeter & Plymouth, 2005
BSc (Combined Honours) Cell Biology & Immunology with Chemistry
University of Plymouth, 1997
- Member of the Royal Society of Chemistry (MRSC)
- Fellow of the Higher Education Academy (FHEA)
- Member of the UK Society for Intravenous Anaesthesia (UK SIVA)
My current roles include:
- Lead for Pharmacology for our PgDip Physician Associate Studies programme
- Module Lead for Personal and Professional Development (PgDip Physician Associate Studies)
- Problem Based Learning Facilitator for Year 1 BMBS students
- Life Science Resource Centre facilitator for Year 2 BMBS students
- Developing and delivering plenaries for the BMBS programme
- Consolidation Week facilitator (Year 1 & Year 2 BMBS students)
- Special Study Unit (SSU) facilitator
- SSU 1 - The formative, introductory SSU completed by Year 1 BMS students
- Working Together for Patients - A Year 3 SSU where BMBS students spend some time working with Professions Allied to Medicine to deepen their understanding of the work of multidisciplinary teams.
- I am School Lead for the Research in Action SSU - A Year 3/4 longitudinal SSU where BMBS students spend time in a research environment, experiencing and developing skills for writing proposals, funding grant applications and displaying their work in a poster format.
- Doctors as Teachers - A Year 3/4 longitudinal SSU in which BMBS students are given the task of developing their own teaching and learning resource, reflecting on their own experiences of teaching and learning and deepening their understanding of pedagogy.
- Contributing to question writing and exam paper review for the Applied Medical Knowledge module (BMBS) and Foundations of Clinical Medicine (PgDip Physician Associate Studies).
- Curriculum development for our postgraduate Physician Associate programme.
Current Research Interests
Population pharmacokinetics & pharmacodynamics, novel drug compounds, anaesthetic drug use in patients at the extremes of weight (paediatric critical care, bariatric surgery patients), health hazards related to use of medical plastics and dental composites (toxicokinetics)
DOCTORAL & POST-DOCTORAL RESEARCH EXPERIENCE
2000-2004 The Pharmacokinetics (PK) and Pharmacodynamics (PD) of Propofol in the Critically Ill Child, a collaboration with Professor Wolf, University of Bristol. I developed a novel solid phase extraction procedure for propofol quantification from 0.1mL whole blood. Three studies were conducted; an initial population PK study in 21 critically ill neonates, infants and children, a follow-up population PK-PD study in 10 infants and children and finally, a population analysis of pooled data (our own PK data plus data provided by 6 international research groups). These studies greatly extended the knowledge of paediatric propofol PK and PD, particularly for the smallest patients.
2003-2006 Pharmacokinetic and Pharmacodynamic Studies of Remifentanil in Paediatric Intensive Care, a collaboration with Professor Wolf, University of Bristol. I developed a novel high performance liquid chromatography assay allowing simultaneously quantification of remifentanil, fentanyl and midazolam from 0.9mL of whole blood. ‘Sparse sampling’ combined with NONMEM population modelling allowed optimal information yield from a restricted total blood sample volume whilst maximising model predictive performance. This study has provided the first description of paediatric remifentanil pharmacokinetics following infusion and has produced a model of drug disposition that can be applied to post-cardiac surgery children aged from 1 month to 9 years of age.
2005-2006 Ketamine Pharmacokinetics in Healthy Volunteers, a collaboration with Dr Absalom, University of Cambridge. I developed a new population based pharmacokinetic model for ketamine in healthy volunteers from pooled data. Retrospective evaluation shows that the predictive accuracy of our new model improves on previous inadequate models (based on suboptimal sampling schemes and non-physiological assumptions). Our new model will shortly undergo prospective evaluation prior to clinical deployment.
Industry-funded Pharmacokinetic-Pharmacodynamic Modelling Projects
I worked with Labopharm, Canada, assisting with the pre-clinical development of a new formulation of propofol.
In collaboration with the pharmaceutical industry (Maruishi, Japan) and with Veeda Clinical Research centre (Plymouth), I provided pharmacokinetic-pharmacodynamic analysis of data from Phase 1 clinical trials of a new sedative-hypnotic drug (MR04A3) and comparator compounds.
Research degrees awarded to supervised students
I currently supervise two research students, Mr Stephen Wileman and Mrs Anfal Alwadi. Both are investigating dental composites as a potential source of human exposure to bisphenol A and plasticiser phthalates. Steve has recently submitted his thesis and Anfal has just begun her studies.
Key publications are highlightedJournals
Other academic activities
I regularly provide reviews for the journals; British Journal of Anaesthesia, Anaesthesia and Anesthesiology. I am a member of the population pharmacokinetic-pharmacodynamic review team for the journal, Pediatric Anesthesia.